Neurocrine Biosciences
NBIX
#1526
Rank
NZ$20.10 B
Marketcap
$201.63
Share price
1.62%
Change (1 day)
-6.24%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $3.22

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.40. In 2022 the company made an earnings per share (EPS) of $2.80 an increase over its 2021 EPS that were of $1.65.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$3.2215.25%
2022$2.8069.47%
2021$1.65-78.21%
2020$7.57990%
2019$0.6981.82%
2018$0.38-113.5%
2017-$2.830.62%
2016-$2.8157.28%
2015-$1.7925.61%
2014-$1.4218.84%
2013-$1.20-1085.71%
2012$0.12-89.71%
2011$1.18-500%
2010-$0.30-86.92%
2009-$2.26-43.48%
2008-$3.99-57.8%
2007-$9.4692.58%
2006-$4.91371.67%
2005-$1.04-52.76%
2004-$2.2136.56%
2003-$1.61-70%
2002-$5.38118.31%
2001-$2.478.4%
2000-$2.2748.86%
1999-$1.53-20%
1998-$1.91-479.31%
1997$0.50

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.63 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.96-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$5.14-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$9.43 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.39 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.23-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.82-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$5.26-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA